Gladius Capital Management’s Merck MRK Stock Holding History

Gladius Capital Management’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.34M	Buy	+61,000	New	+$7.04M	0.33%	75
2024 Q1	–	Sell	-14,100	Closed	-$1.54M	–	378
2023 Q4	$1.54M	Sell	14,100 -27,700	-66%	-$2.88M	0.24%	67
2023 Q3	$4.3M	Buy	41,800 +15,000	+56%	+$1.62M	0.18%	89
2023 Q2	$3.09M	Buy	26,800 +6,700	+33%	+$761K	0.15%	64
2023 Q1	$2.14M	Buy	+20,100	New	+$2.17M	0.12%	82
2021 Q3	–	Sell	-4,600	Closed	-$358K	–	132
2021 Q2	$358K	Sell	4,600 -66,245	-94%	-$4.93M	0.03%	92
2021 Q1	$5.21M	Buy	70,845 +12,157	+21%	+$897K	0.2%	95
2020 Q4	$4.58M	Buy	58,688 +49,675	+551%	+$3.8M	0.23%	99
2020 Q3	$714K	Buy	+9,013	New	+$706K	0.07%	110
2020 Q2	–	Sell	-18,026	Closed	-$1.32M	–	88
2020 Q1	$1.32M	Sell	18,026 -13,519	-43%	-$1.06M	0.14%	75
2019 Q4	$2.74M	Buy	31,545 +9,013	+40%	+$740K	0.17%	86
2019 Q3	$1.81M	Buy	22,532 +15,091	+203%	+$1.21M	0.08%	130
2019 Q2	$602K	Buy	+7,441	New	+$570K	0.04%	125

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gladius Capital Management's MRK Position: Q1 2026 in Review

Gladius Capital Management opened a new position in Merck (MRK) in Q1 2026: 7,500 shares worth $902K. The stake represents 0.04% of the portfolio and ranks #93 among its holdings. This is a return to the name: Gladius Capital Management previously reported a position in MRK as recently as Q1 2025.

Gladius Capital Management first reported a position in MRK in Q2 2018 and has held it in 23 quarters since. The position peaked at $5.16M in Q3 2019. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

Gladius Capital Management held 7,500 shares of Merck worth $902K as of Q1 2026.
Merck was a new Gladius Capital Management position in Q1 2026.
Merck made up 0.04% of Gladius Capital Management's portfolio in Q1 2026, its #93 holding.
Gladius Capital Management first reported a position in Merck in Q2 2018 and has held it in 23 quarters since.
Gladius Capital Management's Merck position peaked at $5.16M in Q3 2019.
3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Gladius Capital Management's 13F filing for Q1 2026, filed 7 May 2026.